Eolo Medical Raises Over $7 Million in Series B Funding Round

Posted on Thursday, August 1st, 2019

August, 2019 – Eolo Medical, an early stage company focused on therapies for advanced COPD treatment, recently announced a major investment of over $7 million (50 Million Chinese Yuan) by China-based Yuexiu Financial Holdings and Ying Lan Capital. Eolo plans to use this money to initiate clinical studies of their proposed Type III implantable device [...]

Read More...

Reprieve Cardiovascular Announces Late-Breaking Acute Heart Failure Clinical Trial Data at Heart Failure 2019 Congress.

Posted on Wednesday, May 22nd, 2019

May 25, 2019 – Reprieve Cardiovascular™, a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure (ADHF), announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure (AHF). The two studies demonstrate that using Reprieve-Guided Diuretic Therapy, the first fully automated fluid [...]

Read More...

Reprieve Cardiovascular Presents Proposed HF Therapy at Med Tech Strategist Innovation Summit

Posted on Wednesday, April 3rd, 2019

Jim Dillon, President & CEO, Reprieve Cardiovascular, and Dr. Howard Levin, President, and Chief Medical Officer, Coridea, presented Reprieve’s innovative approach for heart failure therapy at the Med Tech Strategist Innovation Summit, April 9-11, in Dublin. The conference is recognized as the leading medical technology investment forum in Europe and brings together more than 450 [...]

Read More...